
June 13 (Reuters) - Clarity Pharmaceuticals Ltd CU6.AX:
CLARITY PHARMACEUTICALS LTD - CU-64 SAR-BOMBESIN SAFE, WELL TOLERATED, EFFECTIVE IN DETECTING PROSTATE CANCER
CLARITY PHARMACEUTICALS LTD - ONLY TWO PARTICIPANTS HAD MILD ADVERSE EVENTS RELATED TO CU-64 SAR-BOMBESIN
CLARITY PHARMACEUTICALS LTD - CU-64 SAR-BOMBESIN IDENTIFIED LESIONS IN 35% OF PARTICIPANTS ON SAME-DAY IMAGING